Despite the multitude of treatment options available, patients are often dissatisfied due to failure of achieving optimal control and cost of conventional drugs. According to the European Federation of Neurological Societies (EFNS) guideline, prophylactic treatment should be considered when the quality of life is severely impaired, when two or more attacks occur per month, when migraine attacks do not respond to acute therapy or in case of frequent, very long, or uncomfortable auras. Migraine treatment traditionally includes acute therapy for aborting migraine attacks and prophylactic treatment for reducing the frequency, duration and severity of attacks. European data showed the mean prevalence of migraine among 170,000 adults to be 14.7% (8% in men and 17.6% in women) in France, prevalence was reported to be between 12 to 21% in the Framig III study. US government statistics indicate that migraine affects around one in seven Americans annually. Migraine is a common neurological disorder characterized by severe episodic headaches, which are frequently incapacitating. An improvement of quality of life (Qualité de Vie et Migraine questionnaire) was also observed. The proportion of patients with anxiety and depressive symptoms (Hospital Anxiety and Depression Scale) decreased between baseline phase and third month of supplementation from 61.9% (39/63 patients with information available) to 35% (21/60) for depression and from 52.4% (33/63) to 30% (18/60) for anxiety.
The proportion of patients with a reduction of at least 50% in the number of days with migraine headache was 75% (51/68) after 3 months, with a progressive increase over the period of supplementation (63.2% after 1 month and 70.6% after 2 months). The decrease was progressive over the period of supplementation and significant from first month (1st month: −2.5 days ☓.1, p < 0.0001 2nd month: −3 days ☒.8, p < 0.0001).
Supplementation significantly reduced the number of days with migraine headache during third month of supplementation compared to baseline phase (1.3 days ☑.5 versus 4.9 days ☒.6, p < 0.0001 n = 68 intention to treat primary criterion).
0 kommentar(er)
